论文部分内容阅读
[目的]探讨术前同步放化疗应用于局部中晚期宫颈癌治疗的疗效及安全性。[方法]选取2013年6月至2014年8月局部中晚期宫颈癌患者100例,观察组患者(n=50)给予术前同步放化疗治疗,对照组患者给予新辅助治疗,治疗结束后选择合适的时间进行手术,对比两组患者近期疗效、根治性手术率及手术切缘阴性率、毒副反应发生率及1年生存率。[结果]观察组患者总缓解率为84.00%,对照组患者总缓解率为66.00%(χ~2=8.097,P<0.05)。与对照组对比,观察组患者手术切缘阴性率及手术率均显著升高(P<0.05);两组患者胃肠反应及血液毒性不良反应差异无统计学意义(P>0.05)。随访期间对照组死亡2例,两组患者1年生存率差异无统计学意义(P>0.05)。[结论]同步放化疗应用于局部中晚期宫颈癌的治疗效果优于单纯的辅助化疗,值得进一步研究。
[Objective] To evaluate the efficacy and safety of preoperative chemoradiotherapy in the treatment of locally advanced cervical cancer. [Methods] A total of 100 patients with locally advanced cervical cancer from June 2013 to August 2014 were enrolled. Patients in the observation group (n = 50) received preoperative concurrent chemoradiotherapy and chemotherapy. Patients in the control group received neoadjuvant therapy. After treatment, The appropriate time for surgery, the two groups of patients compared the short-term efficacy, radical surgery and surgical margin negative rate, the incidence of toxic reactions and 1-year survival rate. [Results] The total remission rate was 84.00% in the observation group and 66.00% in the control group (χ ~ 2 = 8.097, P <0.05). Compared with the control group, the negative rate of surgical margins and the surgical rate in the observation group were significantly increased (P <0.05). There was no significant difference in gastrointestinal reactions and adverse reactions of hematological toxicity between the two groups (P> 0.05). There were 2 deaths in the control group during the follow-up period. There was no significant difference in one-year survival rate between the two groups (P> 0.05). [Conclusions] The application of concurrent chemoradiotherapy in locally advanced cervical cancer is better than simple adjuvant chemotherapy, which deserves further study.